MiMedx receives three new US patents for placental tissue allografts

12 June 2013 (Last Updated June 12th, 2013 18:30)

MiMedx Group, a US-based manufacturer of regenerative biomaterial products, has received three new patents for placental tissue allografts from the US Patent Office.

MiMedx Group, a US-based manufacturer of regenerative biomaterial products, has received three new patents for placental tissue allografts from the US Patent Office.

The first, entitled 'Placental Tissue Grafts' with patent number 8,409,626, was issued with a grant date of 2 April 2013, while the other two patents, entitled 'Placental Tissue Grafts' and 'Method for Applying a Label to a Placental Tissue Graft' with numbers 8,460,715 and 8,460,716 respectively, were issued with a grant date of 11 June 2013.

The new patents relate to the firm's placental tissue allografts, including its brands AmnioFix and EpiFix.

Although human amnion / chorion tissue is rich in cytokines and promotes wound healing, the preservation of the biological activities of therapeutic allografts during processing is a key challenge.

MiMedx's proprietary Purion process has solved this challenge, producing dehydrated human amnion / chorion membrane tissue allografts (dHACM).

"The new patents relate to the firm's placental tissue allografts, including its brands AmnioFix and EpiFix."

Purion-processed dHACM preserves biologically active growth factors and regulatory factors that aid its clinical effectiveness in wound healing and other applications.

MiMedx chairman and CEO Parker Petit said; "These three newly issued patents now give us a total of eight dHACM-based US patents that have been issued to MiMedx."

"We are also pleased that our allografts from our proprietary AmnioFix and EpiFix technologies are continuing to gain excellent reception among the physician community and the private and public sector insurance carriers," added Petit.

The company also filed more than 10 new patent applications for its amnion technology.

MiMedx president and COO Bill Taylor said; "Currently, we have in excess of 30 additional patent applications filed with the US Patent Office relating to intellectual property of our AmnioFix and EpiFix technologies."

"We expect to be quite prolific in filing further patent applications related to our designs, methods and processes that preserve the critical anti-inflammatory, barrier, scar formation reduction and enhanced healing properties inherent in amniotic tissue," said Taylor.